Location History:
- Chuo-ku, JP (2012)
- Tokyo, JP (2019 - 2024)
Company Filing History:
6 out of 417 
3 out of 222 
Years Active: 2012-2025
Title: **Yoshiyuki Tenda: A Pioneer in Cancer Treatment Innovations**
Introduction
Yoshiyuki Tenda, a renowned inventor based in Tokyo, Japan, has made significant contributions to the field of biomedical science with a focus on cancer treatment. With a total of five patents to his name, Tenda is celebrated for his innovative approaches to developing bispecific antibodies aimed at targeting cancer cells. His work reflects a deep commitment to advancing therapeutic options for patients suffering from various types of cancer.
Latest Patents
One of Tenda's latest inventions is the **Anti-CLDN4/anti-CD137 bispecific antibody**. This antibody is designed to treat cancer by utilizing an anti-CLDN4 antibody that binds to CLDN4, and an anti-CD137 antibody that binds to CD137. This bispecific antibody not only exhibits strong agonistic activity for CD137 but also promotes the production of interferon γ by T cells, showcasing notable cytotoxic activity against cancer cells expressing CLDN4. Additionally, safety tests demonstrated that the antibody can be safely administered to monkeys, paving the way for potential human applications.
Another significant patent from Tenda is the **Anti-TSPAN8/anti-CD3 bispecific antibody** and **anti-TSPAN8 antibody**. The objective of this invention is to create antibodies that can be used for treatment or prevention in humans. Tenda’s innovative process involved immunizing a human monoclonal antibody-producing mouse with peritoneal disseminated cancer cells from a patient. This led to the development of two antibodies, 16B11 and 16B12, which selectively bind to TSPAN8 on cancer cells. The anti-TSPAN8(16B11)-anti-CD3 bispecific antibody showed promising results both in vitro and in vivo, demonstrating cytotoxic activity against TSPAN8-expressing cancer cells and extending the lifespan of model mice bearing such tumors.
Career Highlights
Throughout his career, Yoshiyuki Tenda has collaborated with notable institutions and companies that have influenced his work in the biomedical field. He has held key roles in **Astellas Pharma GmbH** and the **National Cancer Center**, where he developed his groundbreaking antibody therapies. His commitment to innovation and research has earned him recognition in the scientific community.
Collaborations
In his journey as an inventor, Tenda has collaborated with esteemed colleagues such as **Shinsuke Nakao** and **Masayuki Ito**. Together, they have worked on advancing cancer treatment options, contributing to the development of vital therapeutic strategies that have potential implications for clinical practice.
Conclusion
Yoshiyuki Tenda stands as a pivotal figure in the realm of cancer research and treatment innovations. His inventive spirit and dedication to developing novel therapies have the potential to significantly improve outcomes for cancer patients. With a robust portfolio of patents illustrating his innovative work, Tenda continues to inspire the next generation of scientists and inventors aiming to tackle the challenges posed by cancer.